Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$8.7MFederal grants as PI13 awards
1Patents grantedLatest May 12, 2026
285Papers12,103 citations
Federal awards and patents by year
AwardsPatents
13 awards · $8.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 28, 2025 | NIH | SBIR Phase II A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | $993K | BIOVINC, LLC |
| Apr 22, 2024 | NIH | SBIR Phase II A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | $979K | BIOVINC, LLC |
| Dec 10, 2021 | NIH | SBIR Phase II Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | $989K | BIOVINC, LLC |
| Dec 14, 2020 | NIH | SBIR Phase II Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | $976K | BIOVINC, LLC |
| Jan 13, 2020 | NIH | SBIR Phase II Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | $999K | BIOVINC, LLC |
| Aug 16, 2019 | NIH | STTR Phase I Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer | $225K | BIOVINC, LLC |
| Aug 16, 2018 | NIH | STTR Phase II Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | $750K | BIOVINC, LLC |
| Jul 31, 2018 | NIH | SBIR Phase II Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | $692K | BIOVINC, LLC |
| Jun 12, 2018 | NIH | SBIR Phase I Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis | $225K | BIOVINC, LLC |
| Feb 13, 2018 | NIH | SBIR Phase II Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | $749K | BIOVINC, LLC |
| Mar 15, 2017 | NIH | SBIR Phase II Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | $741K | BIOVINC, LLC |
| Aug 21, 2015 | NIH | SBIR Phase I Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | $150K | BIOVINC, LLC |
| Apr 21, 2015 | NIH | SBIR Phase I Novel Bisphosphonate 18F-PET and PET/optical Dual Modality Probes for Rheumatoid Arthritis Imaging | $225K | BIOVINC, LLC |
2 patents as inventor
- US 12624057BIOVINC, LLCMay 12, 2026
- US BIOVINC, LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#93
Awards as PI#72
Patents#155
Companies
- BIOVINC, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.